Preclinical models evaluated <sup>89</sup>Zr-tracers targeting DLL3 or CDCP1 (an antigen expressed in aggressive neuroendocrine tumours) and <sup>18</sup>F-BnTP (a target of mitochondrial activity) in SCPC subtypes, focusing on translational imaging.<h4>Conclusions</h4>From this review, although still based on limited literature evidence and mostly derived from retrospective and small SCPC sub-cohorts,<sup>18</sup>F-FDG PET/CT currently appears as the most reliable tracer for SCPC, aiding tumor detection and prognostication when PSMA/choline imaging fails. Here, FOLH1 is linked to neuroendocrine neoplasm.